EMA consults on definition of starting materials for specific biological medicines
This article was originally published in SRA
Executive Summary
The European Medicines Agency has published a draft reflection paper to help manufacturers preparing marketing authorisation dossiers understand what would constitute a "starting material" in the case of specific groups of biological medicines1. The paper, which clarifies the definition of starting materials for such products, also addresses the extent to which any variability in the early manufacturing steps for the biologics would be acceptable.
You may also be interested in...
COVID-19 Vaccine Dosing: Pharma Says Follow The Science As It Gathers Data
The UK’s deployment of COVID-19 vaccines has left vaccine manufacturers worried about emerging discussions on dosing strategies that may not be supported by authorized labeling or published clinical data.
India Permits Sale Of Some Devices Beyond Licensing Deadline
Existing importers and manufacturers of certain medical devices can continue marketing their products for six months or until the Indian medtech regulator makes a final decision on their pending licensing applications.
Australia Considers Redefining Central Circulatory System To Align With EU
Differences between how Australia and the EU define “central circulatory system” has resulted in different risk classification levels being assigned to some devices in the two jurisdictions.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: